Last reviewed · How we verify
NCT02864004: EARLY-PUMP
Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)
Phase 3 trial testing Apomorphine in Parkinson's Disease in 134 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Rennes University Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 134 |
| Start date | 3 March 2017 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 January 2025 |
| Sites | 20 locations across France |
Drugs / interventions tested
- Apomorphine (APOMORPHINE) — full drug profile →
- Best Medical Treatment — full drug profile →
Conditions studied
- Parkinson's Disease — all drugs for Parkinson's Disease →
Sponsor
Rennes University Hospital
Who can join
Adults 18 to 65, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to assess the use of the apomorphine pump in earlier stages of Parkinson' Disease (PD), when motor complications have just developed and before patients are significantly affected in their social and occupational functioning. The investigators hypothesize that apomorphine pump is superior in terms of positive impact on quality of life (QoL) to oral medical therapy alone at a relatively early stage of PD, before the appearance of severe disabling motor complications thus favoring the maintain of patients' social and occupational status with a significant positive economic impact of the health system.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Off-time Treatment Options for Parkinson's Disease.
Fabbri M, Barbosa R, Rascol O. · · 2023 · cited 29× · PMID 36633762 · DOI 10.1007/s40120-022-00435-8 -
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.
Auffret M, Drapier S, Vérin M. · · 2018 · cited 29× · PMID 29546602 · DOI 10.1007/s40268-018-0230-3 -
Lipid-based nanoparticles for drug delivery in Parkinson's disease.
Cai H, Liu D, Xue WW, Ma L, et al · · 2024 · cited 7× · PMID 39654878 · DOI 10.1515/tnsci-2022-0359 -
Clinical Trial Highlights - Infusion Therapies.
Prakash N, McFarthing K, Simuni T. · · 2020 · cited 7× · PMID 31903996 · DOI 10.3233/jpd-199005 -
Impact of Infusion Therapies on Quality of Life in Advanced Parkinson's Disease.
Constantin VA, Szász JA, Dulamea AO, Valkovic P, et al · · 2023 · cited 5× · PMID 37727253 · DOI 10.2147/ndt.s422717
Verify or expand the search:
- PubMed search for NCT02864004
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apomorphine
Trials testing the same drug.
- NCT04887467 — Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine · Phase 4 · completed
- NCT03693872 — Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pu · NA · completed
- NCT04786158 — Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) · completed
- NCT02940912 — Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease · Phase 4 · completed
Other recruiting trials for Parkinson's Disease
Currently open trials in the same condition.
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
- NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting
Other Rennes University Hospital trials
Trials by the same sponsor.
- NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
- NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
- NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
- NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
- NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02864004 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
- Last refreshed: 27 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02864004.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing